Use este identificador para citar ou linkar para este item:
http://bdtd.uftm.edu.br/handle/tede/927Registro completo de metadados
| Campo DC | Valor | Idioma |
|---|---|---|
| dc.creator | RODRIGUES, Isac Souza Silva | - |
| dc.creator.ID | 38407695823 | por |
| dc.creator.Lattes | http://lattes.cnpq.br/4080831119115996 | por |
| dc.contributor.advisor1 | NOMELINI, Rosekeila Simões | - |
| dc.contributor.advisor1ID | 03651235602 | por |
| dc.contributor.advisor1Lattes | http://lattes.cnpq.br/0564643325267326 | por |
| dc.contributor.advisor-co1 | MURTA, Eddie Fernando Candido | - |
| dc.contributor.advisor-co1ID | 47668032649 | por |
| dc.contributor.advisor-co1Lattes | http://lattes.cnpq.br/5724192420139830 | por |
| dc.date.accessioned | 2019-11-25T19:47:50Z | - |
| dc.date.issued | 2018-01-16 | - |
| dc.identifier.citation | RODRIGUES, Isac Souza Silva. Níveis de interleucinas no líquido peritoneal em pacientes com neoplasias de ovário. 2018. 74f . Dissertação (Mestrado em Ciências da Saúde) - Programa de Pós-Graduação em Ciências da Saúde, Universidade Federal do Triângulo Mineiro, Uberaba, 2018 . | por |
| dc.identifier.uri | http://bdtd.uftm.edu.br/handle/tede/927 | - |
| dc.description.resumo | INTRODUÇÃO:A neoplasia maligna de ovário é um dos cinco tipos de câncer mais comuns em mulheres e a principal causa de mortalidade causada por doenças malignas ginecológicas em países desenvolvidos. O diagnóstico ocorre com mais frequência em estádios avançados da doença, onde a resposta ao tratamento é menor. Ainda não há uma forma de rastreamento eficaz para se detectar está neoplasia em seu estádio inicial. OBJETIVO: Analisar a dosagem de citocinas (padrão Th1: IL-2, IL-8, e TNF-α; padrão Th2: IL-5, IL-6 e IL-10) no lavado peritoneal e comparar os resultados entre lesões não neoplásicas, neoplasias benignas e malignas primárias de ovário, além de relacionar as dosagem dessas citocinas com parâmetros prognósticos clínicos e patológicos em câncer de ovário. MATERIAL E MÉTODOS: Foram avaliadas 117 pacientes foram avaliadas, divididas em três grupos: lesões não neoplásicas de ovário (n=14), lesões benignas (n= 74), e lesões malignas de ovário (n= 29) pacientes. Montamos um banco de dados a partir dos prontuários com: idade, paridade, status hormonal, tipo histológico, e no caso de tumores malignos, grau histológico, estadiamento (FIGO), e resultados dos ensaios de cada citocina dosada no lavado peritoneal/ascite. Os resultado entre os grupos de lesões não neoplásicas, benignas e malignas foram comparados através de teste Kruskal-Wallis com pós-teste de Dunn e comparações de citocinas com fatores prognósticos foi utilizado o teste de Wilcoxon-Mann-Whitney, consideradas significativas quando o valor de p <0,05. RESULTADOS: Na avaliação das citocinas no lavado peritoneal foi observado que IL-6 e IL-8 foram mais relacionadas ao fatores prognósticos. Níveis mais altos de IL-6 foram relacionados com RNL > 4 (p=0.0311), PLR >200 (p=0.0051), CA125 > 35 U/mL (p=0.0019), anemia (p=0.0027), estádio IIIC (p=0,0203) e SLD ≤24 meses (p=0.0267). Níveis mais altos de IL-8 estiveram relacionados com RNL > 4 (p=0,0241), PLR >200 (p=0,0426) CA125 > 35 U/mL (p=0,0292). CONCLUSÃO: IL-6 e IL-8 no lavado peritoneal estiveram relacionadas com fatores de mau prognóstico. A avaliação dessas citocinas poderia levar o oncologista a individualizar o tratamento das pacientes e ser alvo de estudo para novas terapias em câncer de ovário. | por |
| dc.description.abstract | INTRODUCTION: Malignant neoplasm of ovary is one of the five most common cancers in women and the leading cause of gynaecological malignancy in developed countries. Ascites is an inflammatory environment rich in mediators of inflammation, and inflammatory cytokines could be used as prognostic factors. OBJECTIVE: The objectives of the study were to analyze the dosage of a cytokines panel (IL2, IL5, IL6, IL8, IL10 and TNF-α) in the peritoneal fluid and relate the dosage of these cytokines to clinical and clinical prognostic parameters pathologies in ovarian cancer. MATERIAL AND METHODS: We evaluated 117 patients, divided into three groups: non-neoplastic ovarian lesions (n = 14), benign lesions (n = 74), and malignant ovarian lesions (n = 29). We created a database with age, parity, hormonal status, histological type and in the case of malignant tumours, tumour grade, stage (FIGO) and test results of each cytokine analysed in ascites or peritoneal lavage. The results between the groups of non-neoplastic, benign and malignant lesions were compared through the Kruskal-Wallis test with Dunn post-test, cytokines and prognostic factors comparisons was used the Wilcoxon-Mann-Whitney test and considered significant when p <0.05. RESULTS: We evaluated 29 patients with ovarian cancer. Higher levels of IL-6 were related to RNL > 4 (p = 0.0311), RPL > 200 (p = 0.0051), CA-125 levels > 35 U / mL (p = 0.0019), stage IIIC (p = 0.0203), and SLD ≤ 24 months (p = 0.0267). In the evaluation of IL-8, higher levels of this cytokine were related to NLR > 4 (p = 0.0241), RPL > 200 (p = 0.0426), and CA125 > 35U / mL (p = 0.0292). CONCLUSION: IL 6 and IL 8 in the peritoneal lavage were related to poor prognostic factors. The evaluation of these cytokines may lead the oncologist to individualize the adjuvant treatment making it more or less aggressive; depending on the profile of each patient, as well as these cytokines may be the target of new therapies in ovarian cancer. | eng |
| dc.description.sponsorship | Coordenação de Aperfeiçoamento de Pessoal de Nível Superior | por |
| dc.description.sponsorship | Fundação de Amparo à Pesquisa do Estado de Minas Gerais | por |
| dc.description.sponsorship | Conselho Nacional de Desenvolvimento Científico e Tecnológico | por |
| dc.format | application/pdf | * |
| dc.thumbnail.url | http://bdtd.uftm.edu.br/retrieve/6247/Dissert%20Isac%20S%20S%20Rodrigues.pdf.jpg | * |
| dc.language | por | por |
| dc.publisher | Universidade Federal do Triângulo Mineiro | por |
| dc.publisher.department | Instituto de Ciências da Saúde - ICS::Programa de Pós-Graduação em Ciências da Saúde | por |
| dc.publisher.country | Brasil | por |
| dc.publisher.initials | UFTM | por |
| dc.publisher.program | Programa de Pós-Graduação em Ciências da Saúde | por |
| dc.relation.references | ADAMS, S. F. et al. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol., v. 123, n. 5, p. 213–223, 2011. ALI-FEHMI, R. et al. Molecular typing of epithelial ovarian carcinomas using inflammatory markers. Cancer, v. 117, n. 2, p. 301–309, 2011. AMERICAN CANCER SOCIETY. Survival Rates for Ovarian Cancer by Stage. Disponível em: <http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-survival-rates>. Acesso em: 4 nov. 2017. AUDEH, M. W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. The Lancet, v. 376, n. 9737, p. 245–251, 2010. BARNETT, J. C. et al. Ovarian cancer tumor infiltrating T-regulatory (Treg) cells are associated with a metastatic phenotype. Gynecologic Oncology, v. 116, n. 3, p. 556–562, 2010. BAST, R. C.; HENNESSY, B.; MILLS, G. B. The biology of ovarian cancer: new opportunities for translation. Nature Reviews Cancer, v. 9, n. 6, p. 415–428, 2009. BOYD, J. et al. Clinicopathologic Features of BRCA-Linked and Sporadic Ovarian Cancer. Jama, v. 283, n. 17, p. 2260, 2000. BU, M. et al. Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8+ T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression. Tumor Biology, v. 37, n. 3, p. 3949–3956, 2015. CANNISTRA, S. A. Cancer of the Ovary. New England Journal of Medicine, v. 351, n. 24, p. 2519–2529, 2004. CHARLES, K. A. et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest, v. 119, n. 10, p. 3011–23, 2009. CHO, H. et al. CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer - CA19-9 level in teratoma. Medical science monitor : international medical journal of experimental and clinical research, v. 19, p. 230–5, 2013. CHO, H.; KYUNG, M. S. Serum CA19-9 as a Predictor of Malignancy in Primary Ovarian Mucinous Tumors: A Matched Case-Control Study. Medical Science Monitor, v. 20, p. 1334–1339, 2014. CHUDECKA-GŁAZ, A. M. et al. Assessment of selected cytokines, proteins, and growth factors in the peritoneal fluid of patients with ovarian cancer and benign gynecological conditions. OncoTargets and Therapy, v. 8, p. 471–485, 2015. CURIEL, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, v. 10, n. 9, p. 942–949, 2004. DAVID, Y. BEN et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. Journal of Clinical Oncology, v. 20, n. 2, p. 463–466, 2002. DELEEUW, R. J. et al. CD25 Identifies a Subset of CD4+FoxP3- TIL That Are Exhausted Yet Prognostically Favorable in Human Ovarian Cancer. Cancer Immunology Research, v. 3, n. 3, p. 245–253, 2015. DIRICAN, A. et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? International Journal of Clinical Oncology, v. 20, n. 1, p. 70–81, 2015. DRAPKIN, R. et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Research, v. 65, n. 6, p. 2162–2169, 2005. DUFFY, S. A. et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer, v. 113, n. 4, p. 750–757, 2008. EICHTEN, A. et al. Resistance to anti-VEGF therapy mediated by autocrine IL6/STAT3 signaling and overcome by IL6 blockade. Cancer Research, v. 76, n. 8, p. 2327–2339, 2016. EVANS, D. G. et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. Journal of medical genetics, v. 46, p. 593–597, 2009. FENG, Z. et al. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proceedings of the National Academy of Sciences, v. 108, n. 2, p. 686–691, 2011. FISHER, D. T. et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways fortrafficking of cytotoxic T cells. J Clin Invest, v. 121, n. 10, p. 3846–3859, 2011. FONG, P. C. et al. Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. Journal of Clinical Oncology, v. 28, n. 15, p. 2512–2519, 2010. GALGANO, M. T.; HAMPTON, G. M.; FRIERSON, H. F. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Modern Pathology, n. April, p. 847–853, 2006. GALLAGHER, D. J. et al. Survival in epithelial ovarian cancer: A multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Annals of Oncology, v. 22, n. 5, p. 1127–1132, 2011. GAO, G. et al. Chronic stress promoted the growth of ovarian carcinoma via: Increasing serum levels of norepinephrine and interleukin-10 and altering nm23 and NDRG1 expression in tumor tissues in nude mice. BioScience Trends, v. 7, n. 1, p. 56–63, 2013. GIROLIMETTI, G. et al. BRCA-associated ovarian cancer: From molecular genetics to risk management. BioMed Research International, v. 2014, 2014. GIUNTOLI, R. L. et al. Ovarian cancer-associated ascites demonstrates altered immune environment: Implications for antitumor immunity. Anticancer Research, v. 29, n. 8, p. 2875–2884, 2009. GOVINDARAJ, C. et al. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clinical Immunology, v. 149, n. 1, p. 97–110, 2013. GUPTA, M. et al. TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: Evidence for an inflammatory pathway of ovarian carcinogenesis? Human Pathology, v. 54, p. 82–91, 2016. HAGEMANN, T. et al. “Re-educating” tumor-associated macrophages by targeting NF-κB. The Journal of Experimental Medicine, v. 205, n. 6, p. 1261–1268, 2008. HAMED, E. O. et al. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagnostic pathology, v. 8, p. 11, 2013. HANASH, S. M.; PITTERI, S. J.; FACA, V. M. Mining the plasma proteome for cancer biomarkers. Nature, v. 452, n. 7187, p. 571–579, 2008. HUANG, F. et al. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors. Nucleic Acids Research, v. 44, n. 9, p. 4189–4199, 2016. HWANG, J. R. et al. Upregulation of CD9 in ovarian cancer is related to the induction of TNF-α gene expression and constitutive NF-κB activation. Carcinogenesis, v. 33, n. 1, p. 77–83, 2012. INCA, I. N. DE C. INCA - Instituto Nacional de Câncer - Estimativa 2016. [s.l: s.n.]. JAMMAL, M. et al. Immunohistochemical staining of tumor necrosis factor-α and interleukin-10 in benign and malignant ovarian neoplasms. Oncology Letters, v. 9, n. 2, p. 979–983, 2014. JENSEN, R. B.; CARREIRA, A.; KOWALCZYKOWSKI, S. C. Purified human BRCA2 stimulates RAD51-mediated recombination. Nature, v. 467, n. 7316, p. 678–683, 2010. JUNG, S. IL. Ultrasonography of ovarian masses using a pattern recognition approach. Ultrasonography, v. 34, n. 3, p. 173–182, 2015. KIM, S. et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature, v. 457, n. 7225, p. 102–106, 2009. KIM, S. et al. Carcinoma Produced Factors Activate Myeloid Cells via TLR2 to Stimulate Metastasis. Nature, v. 457, n. 7225, p. 102–106, 2010. KOENSGEN, D. et al. Cytokine Polymorphism of the IL-8 gene and the risk of ovarian cancer. Cytokine, v. 71, n. 2, p. 334–338, 2015. KOH, C.-H. et al. Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer. British Journal of Cancer, v. 113, n. 1, p. 150–158, 2015. KOLOMEYEVSKAYA, N. et al. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecologic Oncology, v. 138, n. 2, p. 352–357, 2015. KULBE, H. et al. The inflammatory cytokine tumor necrosis factor-?? generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Research, v. 67, n. 2, p. 585–592, 2007. KULBE, H. et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Research, v. 72, n. 1, p. 66–75, 2012. KURMAN, R. J.; SHIH, I. M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - Shifting the paradigm. Human Pathology, v. 42, n. 7, p. 918–931, 2011. KWA, M. et al. Ovarian Cancer in BRCA Mutation Carriers: Improved Outcome After Intraperitoneal (IP) Cisplatin. Annals of Surgical Oncology, v. 21, n. 5, p. 1468–1473, 2014. LANE, D. et al. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC cancer, v. 15, n. 1, p. 492, 2015. LEDERMANN, J. A. PARP inhibitors in ovarian cancer. Annals of Oncology, v. 27, n. November, p. i40–i44, 2016. LIANG, B. et al. Circulating VEGF as a biomarker for diagnosis of ovarian cancer: A systematic review and a meta-analysis. OncoTargets and Therapy, v. 8, p. 1075–1082, 2015. LIAO, W. C. et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clinical Cancer Research, v. 14, n. 2, p. 428–434, 2008. LIU, C. Z. et al. Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer. Chinese Journal of Cancer Research, v. 24, n. 2, p. 130–137, 2012. LORD, C. J.; ASHWORTH, A. The DNA damage response and cancer therapy. Nature, v. 481, n. 7381, p. 287–294, 2012. LU, D. et al. Comparison of candidate serologic markers for type i and type II ovarian cancer. Gynecologic Oncology, v. 122, n. 3, p. 560–566, 2011. MAGWOOD, A. C.; MUNDIA, M. M.; BAKER, M. D. High levels of wild-type BRCA2 suppress homologous recombination. Journal of Molecular Biology, v. 421, n. 1, p. 38–53, 2012. MALEK, T. R.; CASTRO, I. Interleukin-2 Receptor Signaling: At the Interface between Tolerance and ImmunityImmunityElsevier Inc., , 2010. MARTINS-FILHO, A. et al. Role of Intracystic Cytokines and Nitric Oxide in Ovarian Neoplasms. Scandinavian Journal of Immunology, 2017. MASOUMI-MOGHADDAM, S. et al. Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring. Journal of Ovarian Research, v. 8, p. 58, 2015. MATTE, I. et al. Profiling of cytokines in human epithelial ovarian cancer ascites. American journal of cancer research, v. 2, n. 5, p. 566–80, 2012. MAVADDAT, N. et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, v. 21, n. 1, p. 134–147, 2012. MEINHOLD-HEERLEIN, I.; HAUPTMANN, S. The heterogeneity of ovarian cancer. Archives of Gynecology and Obstetrics, v. 289, n. 2, p. 237–239, 2014. MICHALAKI, V. et al. Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. British Journal of Cancer, p. 2312–2316, 2004. MURTA, E. F. C.; NOMELINI, R. S. Early diagnosis and predictors of malignancy of adnexal masses. Current opinion in obstetrics & gynecology, v. 18, n. 1, p. 14–9, 2006. NAYLOR, M. S. et al. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. The Journal of clinical investigation, v. 91, n. 5, p. 2194–206, 1993. NAZ, S. et al. Role of peritoneal washing cytology in ovarian malignancies: correlation with histopathological parameters. World Journal of Surgical Oncology, v. 13, n. 1, p. 315, 2015. NEGRIER, S. et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: Prognostic value of interleukin-6 - From the Groupe Français d’Immunothérapie. Journal of Clinical Oncology, v. 22, n. 12, p. 2371–2378, 2004. NUNES, N. et al. Use of IOTA simple rules for diagnosis of ovarian cancer: Meta-analysis. Ultrasound in Obstetrics and Gynecology, v. 44, n. 5, p. 503–514, 2014. PANDIT, R. et al. Non-Small-Cell Lung Cancer Associated With Excessive Eosinophilia and Secretion of Interleukin-5 as a Paraneoplastic Syndrome. American journal of hematology, v. 82, n. 9, p. 807–811, 2007. PAULL, T. T. et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Current Biology, v. 10, n. 15, p. 886–895, 2000. PIURA, B. et al. Distinct expression and localization of TNF system in ovarian carcinoma tissues: Possible involvement of TNF-α in morphological changes of ovarian cancerous cells. Anticancer Research, v. 34, n. 2, p. 745–752, 2014. ROETT, M. A.; EVANS, P. Ovarian Cancer : An Overview. American Academy of Family Physicians, v. 80, n. 6, p. 609–616, 2009. ROSEN, D. G. et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic Oncology, v. 99, n. 2, p. 267–277, 2005. ROSENBERG, S. A. IL-2: The First Effective Immunotherapy for Human Cancer. The Journal of Immunology, v. 192, n. 12, p. 5451–5458, 2014. ROSENTHAL, A. N. et al. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. Journal of Clinical Oncology, p. JCO.2016.69.9330, 27 fev. 2017. RUGGERI, G. et al. HE4 and epithelial ovarian cancer: Comparison and clinical evaluation of two immunoassays and a combination algorithm. Clinica Chimica Acta, v. 412, n. 15–16, p. 1447–1453, 2011. SAFRA, T. et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther, v. 10, n. 10, p. 2000–2007, 2011. SAKAGUCHI, S. et al. FOXP3+ regulatory T cells in the human immune system. Nature Reviews Immunology, v. 10, n. 7, p. 490–500, 2010. SANGUINETE, M. M. M. et al. Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer. Immunological Investigations, v. 46, n. 7, p. 677–688, 2017. SELVENDIRAN, K. et al. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. International Journal of Cancer, v. 125, n. 9, p. 2198–2204, 2009. SHIH, I.-M.; KURMAN, R. J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. The American journal of pathology, v. 164, n. 5, p. 1511–8, 2004. SIEGEL, R. L.; MILLER, K. D.; JEMAL, A. Cancer Statistics, 2017. CA: a cancer journal for clinicians, v. 67, n. 1, p. 7–30, 2017. SIEGMUND, D. et al. Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis. Cell Death and Disease, p. 1–10, 2016. SINGHA, B. et al. IKK inhibition increases bortezomib effectiveness in ovarian cancer. Oncotarget, v. 6, n. 28, p. 26347–58, 2015. STAPLES, J.; GOODMAN, A. PARP Inhibitors in Ovarian Cancer. Ovarian Cancer-A Clinical and Translational Update. InTech, 2013. STATHOPOULOS, G. T. et al. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. American Journal of Respiratory and Critical Care Medicine, v. 182, n. 10, p. 1273–1281, 2010. STONE, R. L. et al. Paraneoplastic Thrombocytosis in Ovarian Cancer. New England Journal of Medicine, v. 366, n. 7, p. 610–618, 2012. SUGIYAMA, T.; KOWALCZYKOWSKI, S. C. Rad52 protein associates with replication protein A (RPA)-single-stranded DNA to accelerate Rad51-mediated displacement of RPA and presynaptic complex formation. Journal of Biological Chemistry, v. 277, n. 35, p. 31663–31672, 2002. TAN, D. S. P. et al. “BRCAness” syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. Journal of Clinical Oncology, v. 26, n. 34, p. 5530–5536, 2008. TANIGUCHI, K.; KARIN, M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in Immunology, v. 26, n. 1, p. 54–74, 2014. TEW, W. P. et al. Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study. Cancer, v. 120, n. 3, p. 335–343, 2014. TIMMERMAN, D. et al. Subjective assessment of adnexal masses with the use of ultrasonography: An analysis of interobserver variability and experience. Ultrasound in Obstetrics and Gynecology, v. 13, n. 1, p. 11–16, 1999. TORRE, L. A. et al. Global Cancer Statistics, 2012. CA: a cancer journal of clinicians., v. 65, n. 2, p. 87–108, 2015. TRABERT, B. et al. Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecologic Oncology, v. 135, n. 2, p. 297–304, 2014. TSAI-TURTON, M. et al. P53 Autoantibodies, Cytokine Levels and Ovarian Carcinogenesis. Gynecologic Oncology, v. 114, n. 1, p. 12–17, 2009. TUTT, A. et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO Journal, v. 20, n. 17, p. 4704–4716, 2001. VALENTIN, L. Pattern recognition of pelvic masses by gray-scale ultrasound imaging: The contribution of Doppler ultrasound. Ultrasound in Obstetrics and Gynecology, v. 14, n. 5, p. 338–347, 1999. VAN CALSTER, B. et al. Polytomous diagnosis of ovarian tumors as benign, borderline, primary invasive or metastatic: Development and validation of standard and kernel-based risk prediction models. BMC Medical Research Methodology, v. 10, 2010. VAN CALSTER, B. et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. Bmj, v. 349, n. oct07 3, p. g5920–g5920, 2014. VERGOTE, I. et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet, v. 357, n. 9251, p. 176–182, 2001. WANG, Y. et al. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine, v. 59, n. 1, p. 145–155, 2012. WILLIAMS, K. A. et al. Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival. PLoS ONE, v. 9, n. 2, 2014. WU, S. et al. Tumor necrosis factor a as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor a expression. Cancer Res., v. 53, p. 1939–1944, 1993. YAMANE, K.; KATAYAMA, E.; TSURUO, T. The BRCT regions of tumor suppressor BRCA1 and of XRCC1 show DNA end binding activity with a multimerizing feature. Biochemical and biophysical research communications, v. 279, p. 678–684, 2000. YAN, B. et al. Tumor necrosis factor-α is a potent endogenous mutagen that promotes cellular transformation. Cancer Research, v. 66, n. 24, p. 11565–11570, 2006. YIGIT, R. et al. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. European Journal of Cancer, v. 47, n. 12, p. 1883–1889, 2011. YIN, Y. Z.; WANG, Y. C. Analysis of behaviour of steel beams with web openings at elevated temperatures. Steel and Composite Structures, v. 6, n. 1, p. 15–31, 2006. YOSHIDA, K.; MIKI, Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Science, v. 95, n. 11, p. 866–871, 2004. ZAYNAGETDINOV, R. et al. Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. Cancer Research, v. 75, n. 8, p. 1624–1634, 2015. | por |
| dc.rights | Acesso Aberto | por |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
| dc.subject | IL-6. | por |
| dc.subject | IL-8. | por |
| dc.subject | Fatores prognósticos. | por |
| dc.subject | Câncer de ovário citocinas. | por |
| dc.subject | Prognosis. | eng |
| dc.subject | Ovarian neoplasms. | eng |
| dc.subject | Cytokines. | eng |
| dc.subject.cnpq | Ciências da Saúde | por |
| dc.title | Níveis de interleucinas no líquido peritoneal em pacientes com neoplasias de ovário | por |
| dc.type | Dissertação | por |
| Aparece nas coleções: | Programa de Pós-Graduação em Ciências da Saúde | |
Arquivos associados a este item:
| Arquivo | Descrição | Tamanho | Formato | |
|---|---|---|---|---|
| Dissert Isac S S Rodrigues.pdf | Dissert Isac S S Rodrigues | 1,37 MB | Adobe PDF |  Visualizar/Abrir |
Este item está licenciada sob uma Licença Creative Commons
